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background: Low density lipoprotein cholesterol (LDL-C) is a risk factor for cardiovascular (CV) disease. Maximal treatment of statins 
is the recommended therapy for high risk patients, such as those with prior acute coronary syndrome (ACS) or ischemic stroke (IS). The 
objective was to determine an association between LDL-C and the risk of non-fatal recurrent outcomes in high risk patients on high dose 
statins.
methods:  This was a retrospective study of commercially insured patients 30 years and older from 1/1/2005 - 05/30/2013. Patients on 
high dose statins following an incident ACS or IS were followed for recurrent, non-fatal MI, UA, IS and composite CV events. Adjusted Cox 
models were used to estimate the risk of outcomes.
Results:  Of 8,694 patients with ACS/IS, 4,621 were on high dose statin therapy during follow-up. In post-ACS/IS patients on high dose 
statins, higher LDL-C was associated with a risk of MI and composite CV event (see table). In post-ACS patients on high dose statins, 
higher LDL-C was associated with risk of any recurrent CV event. Higher LDL-C was associated with increased risk for recurrent IS and UA 
among the ACS/IS group.
conclusion:  In high risk patients on high dose statins, LDL-C level was associated with risk of subsequent CV events. Lowering of LDL-C 
beyond that typically achievable with a maximal statin dose may be important for this group of patients to reduce their risk of recurrent CV 
events.
Outcome Post ACS (per 10 mg/dl increase in LDL) Post ACS/IS(per 10 mg/dl increase in LDL)
Composite CV 1.10 (1.01 - 1.19) 1.09 (1.01 - 1.16)
MI 1.09 (1.00 - 1.20) 1.10 (1.00 - 1.20)
UA 1.17 (0.995 - 1.40) 1.13 (0.994 - 1.33)
IS 1.09 (0.996 - 1.22)
Adjusted for age, gender, hypertension, smoking, diabetes, obesity, baseline dyslipidemia
